Study Status: Withdrawn
Recruit Status: Withdrawn
Study Type: Interventional
Official Title: Pasireotide Treatment for Insulin Producing Pancreatic Neuro-endocrine Tumor
Brief Summary: Pasireotide binds to somatostatin receptors sst2 and sst5, which can lead to significant hyperglycemia. The investigators would like to administer pasireotide as a treatment for refractory hypoglycemia in the setting of metastatic insulin-producing pancreatic neuro-endocrine tumor.